We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




More Accurate PET Imaging Biomarker Developed for Detecting Prostate Cancer

By MedImaging International staff writers
Posted on 01 Feb 2016
Print article
Positron Emission Tomography (PET) imaging combined with a new experimental agent can detect 97% of prostate cancers—more than those detected by pathologists when examining prostate glands that were excised.

The findings were published online in the journal Urology. The new method is better at detecting prostate cancer than any radiographical, biopsy or blood test currently in use. The study cohort consisted of 25 men suffering from prostate cancer who opted to have their prostate glands removed in a radical prostatectomy operation. Before the operation the men underwent the new imaging test.

The researchers from the Thomas Jefferson University (Philadelphia PA, USA) compared the results of the imaging test, and the examination by the pathologists. The imaging test uses a new biomarker, 64Cu-TP3805, and is administered to patients intravenously before they undergo a PET/CT (Computed Tomography) scan. The biomarker attaches itself to VPAC1 receptors on the surface of cancer cells. In addition, a radiation emitting copper peptide, Cu-64, is hooked onto the biomarker TP3805. PET Imaging can then be used to find where in the prostate the 64Cu-TP3805 has attached itself to cancer cells. The radioactive agent Cu-64 decays rapidly and has a lower whole-body radiation risk than a CT scan.

The results of the study showed that the new test identified 97%, or 105 out of 107 cancerous lesions found by the pathologists in the excised prostate glands, and nine additional lesions that were not found in the pathologic exam. The researchers also successfully investigated the use of 64Cu-TP3805 in human breast cancer, and are investigating the use of the test in animal models of bladder and lung cancer.

Senior investigator of the study, Mathew Thakur, PhD, professor of Radiology at the Thomas Jefferson University Sidney Kimmel Medical College, said, “There is a critical need for an accurate method to detect and stage prostate cancer so that the disease can be precisely managed. We believe this method has that potential. Current tests now used are inexact because they all require an invasive biopsy and these costly biopsies—which have the potential for complications—can miss 66% of cancers. It is hard to believe that hundreds of thousands of patients in the US have been relying on biopsies to dictate their treatment, when two-thirds of these tests do not accurately reflect what is happening inside the prostate. Results of this study exceeded our goal of detecting 80% of cancers seen pathologically, and provided us with real insights into how prostate cancer can be accurately imaged. A larger study that confirms these exciting findings should be conducted.”

Related Links:

Thomas Jefferson University


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Ultrasound Table
Ergonomic Advantage (EA) Line
New
Ultrasound Table
Powered Ultrasound Table-Flat Top
Oncology Information System
RayCare

Print article

Channels

Radiography

view channel
:	Image: The AI model could be a valuable adjunct to human radiologists in breast cancer diagnoses and risk prediction (Photo courtesy of 123RF)

AI Model Predicts 5-Year Breast Cancer Risk from Mammograms

Approximately 13% of U.S. women, or one in every eight, are predicted to develop invasive breast cancer over their lifetime, with 1 in 39 women (3%) succumbing to the illness, according to the American... Read more

General/Advanced Imaging

view channel
Image: The CIARTIC Move self-driving mobile C-arm has received FDA clearance (Photo courtesy of Siemens)

Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery

Intraoperative imaging faces significant challenges due to staff shortages and the high demands placed on surgical teams in the operating room (OR). A common challenge during many OR procedures is the... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.